Palm Beach, FL 7/18/12 (StreetBeat) – Soligenix Inc (OTCBB:SNGX) has been awarded a Small Business Innovation Research grant from the National Institute of Allergy and Infectious Diseases (NIAID). Soligenix is a development stage biopharmaceutical company, and this 2-year $600,000 grant is given to support the preclinical development of its OrbeShieldTM product as a treatment for gastrointestinal acute radiation syndrome (GIARS).
Acute GIARS develops from exposure to high dose radiation following a serious nuclear event. Currently, there’s no effective therapy approved for the treatment of this life-threatening consequence.
"We are encouraged with the promising survival results observed to date with OrbeShield™ in the beagle model as a post-exposure therapy for the treatment of GI ARS," stated Christopher J. Schaber, PhD, President and CEO of Soligenix. "With renewed support from NIAID, we look forward to working with Dr. Georges to continue development of OrbeShield™ with the aim of addressing this critical unmet medical need."
Please contact www.thestreetbeat.com for interest in our latest investor relations platform the “CEO Interview Series” with its host Steve Kanaval. The package includes a one-on-one interview with a seasoned industry professional; published segment to our web site with embedded audio/video file; and a compressed file that can be easily e-mailed out to your current and/or potential investors. Please e-mail email@example.com or call (662) 392-0740 for pricing and scheduling.